CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!

09/12/2015 - 3 minutes

Wow! 55 of 59 patients in a Novartis trial experienced complete remission in one of the largest investigational CAR-T therapies for children with relapsed/refractory acute lymphoblastic leukemia (ALL).

leukemia_cart_novartis_ctl019_trialThese are the latest findings from an ongoing phase II study of CTL019, an investigational chimeric antigen receptor T-cell (CAR-T) therapy, further support its potential in the treatment of children and young adults with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

Developed at University of Pennsylania’s Abramson Cancer Center and the Perelman School of Medicine (US), CTL019 was made as an autologous (one patient, one therapy) CAR-T candidate to target the CD19 tumeric antigen. CTL019 has previously demonstrated great phase I results for other blood cancers like Chronic lyphocytic leukemia (CLL) back in 2011. However, results from this study were promising, but no where near as dramatic as the phase II trial for r/r ALL.

The ongoing study of CTL019 in pediatric patients with r/r ALL is being led by Stephan Grupp at the Children’s Hospital of Philadelphia (CHOP).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member